- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
A Closer Look at IL-17 Inhibitors in Psoriasis : Episode 2
Opinion
Video
Mechanism of Action Differences Among IL-17 Inhibitors
Panelists discuss how IL-17 inhibitors differ in their targets within the IL-17 pathway. Secukinumab and ixekizumab block IL-17A, reducing inflammation in psoriasis and arthritis. Brodalumab inhibits IL-17RA, affecting multiple IL-17 cytokines, but carries suicide risk warnings. Bimekizumab targets IL-17A and IL-17F, potentially enhancing efficacy but with added risk of infections. These differences impact efficacy, safety, and patient selection in inflammatory diseases.
Video Player is loading.
Video content above is prompted by the following:
- How do the mechanisms of action of the approved IL-17 inhibitors differ from one another, and how might these differences translate in terms of efficacy and/or safety?
- Secukinumab (IL-17A inhibitor)—approved 2015
- Ixekizumab (IL-17A inhibitor)—approved 2016
- Brodalumab (IL-17RA inhibitor)—approved 2017
- Bimekizumab (IL-17A and IL-17F inhibitor)—approved 2023
Related Videos
Utility of Molecular Testing in Skin Cancer Risk Assessment
Limitations and Challenges in Skin Cancer Staging Systems
Talking to Patients About the Safety of JAK Inhibitors in Atopic Dermatitis
The Role of IL-17 in Psoriasis Pathogenesis
Navigating the Boxed Warning for the JAK Inhibitor Class
Personalized Photoprotection Based on Patient Factors
Impact of Oxidative Stress on Skin Health and the Utility of Antioxidants
Laboratory Monitoring for JAK Inhibitors and Key Takeaways
Options for Eyebrow and Eyelash Regrowth in a 32-Year-Old Female With Alopecia Areata
Efficacy, Safety, and Role in Therapy of JAK Inhibitors for Atopic Dermatitis
Related Content
